Arecor Therapeutics PLC (AIM:AREC) said its proprietary insulin products, AT247 and AT278, have been granted a patent by the United States Patent and Trademark Office.
Patent US 11278624 will protect the novel formulations of the products, which chief scientific officer Dr Jan Jezek explained are based on a combination of existing insulin analogues and the company’s innovative formulation science.
They offer potential “to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes”, Jezek said.
“As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products.
“This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress.”
Arecor added that it has already built a strong patent portfolio to protect its Arestat technology platform and its proprietary pipeline products, with 36 patent families, including at least 50 in Europe, the US and in other key territories.
The intellectual property behind these patents is “robust” and directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use, the company added.
The board’s strategy is to generate a “fortress of both narrow and broad interrelated IP rights” that cover the features of these insulin products.